Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Clin Immunol. 2013 Mar 6;147(2):105–119. doi: 10.1016/j.clim.2013.02.015

Figure 5. Ex vivo suppression by CD4+CD25+ Tregs remains unaffected during first 72h of GA therapy.

Figure 5

Increasing numbers of CD4+CD25+ Tregs, isolated from the indicated cohorts were used in anti-CD3 stimulated CFSE-based suppression assays using third-party Teff cells and irradiated APC. Representative dot plots from a GA-treated patient is shown in panel A. Proliferation percentages in the dot plots indicate gated percentages of CD4+/CFSE low (proliferating) cells. Percent proliferative responses were normalized to the response without suppressors (defined as 100%), indicated as 1:0 in the dot plots and %suppression was calculated (also indicated). Panel B represents %suppression by CD4+CD25+ Treg cells isolated from HD, untreated and GA-treated MS patients.